http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-2009270439-A1
Outgoing Links
Predicate | Object |
---|---|
assignee | http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_d0767fc95a96ba08e843bfdc3ac39b38 |
classificationCPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-473 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-485 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P43-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P25-28 |
classificationIPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P25-28 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-473 |
filingDate | 2008-09-16-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
inventor | http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_24bd496f1e9139a645a9eb8d2e19c10b |
publicationDate | 2009-10-29-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
publicationNumber | US-2009270439-A1 |
titleOfInvention | Prophylactic/therapeutic agent for alzheimer's disease |
abstract | A medicament effective for inhibiting onset of Alzheimer disease via intracellular aggregation mechanism is provided. A medicament for prophylaxis and treatment of Alzheimer disease comprising as an active ingredient apomorphine hydrochloride wherein cell death dependent upon intracellularly accumulated amyloid β proteins and/or p53 is inhibited; and/or wherein a level of intracellularly accumulated amyloid β proteins and/or phosphorylated tau proteins is lowered to improve energy production, protein metabolism and synaptic function of neurons so as to ameliorate the recognition capacity such as defects of memory. A medicament for prophylaxis and treatment of Alzheimer disease according to the present invention may allow for eradicative treatment of Alzheimer disease due to its inhibition of intracellular coagulation and accumulation of amyloid β proteins and intracellular activation of proteasome, and even prior to occurrence of massive neuronal death, may improve the function per se of neurons by reducing intracellularly accumulated amyloid β proteins to thereby contribute amelioration of the recognition function of Alzheimer disease patients. |
isCitedBy | http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-11052154-B2 http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-10976306-B2 http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-11007269-B2 |
priorityDate | 2006-03-16-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
type | http://data.epo.org/linked-data/def/patent/Publication |
Incoming Links
Total number of triples: 198.